Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease

Neurobiology of Disease

Volumn 41, Issue 1, 2011, Pages 43-50

  Hathorn, Tyisha ^a   Snyder Keller, Abigail ^a,b,c   Messer, Anne ^a,b,c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b WADSWORTH CENTER   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Brain derived neurotrophic factor; Histone deacetylase inhibitor; Huntington's disease; Nicotinamide; Peroxisome proliferator activated receptor gamma coactivator 1 alpha; Vitamin

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DRINKING WATER; HUNTINGTIN; MESSENGER RNA; NICOTINAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY EQUILIBRIUM; BRAIN TISSUE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENERGY METABOLISM; FEMALE; GENE EXPRESSION REGULATION; HUNTINGTON CHOREA; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; OPEN FIELD TEST; OSMOTIC PUMP; PHENOTYPE; PRIORITY JOURNAL; PROTECTION; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; RECEPTOR UPREGULATION; ROTAROD TEST; TRANSCRIPTION REGULATION; WEIGHT REDUCTION;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIAL DISEASES; NIACINAMIDE; TRANS-ACTIVATORS; UP-REGULATION; VITAMIN B COMPLEX;

EID: 78349291479     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.08.017     Document Type: Article

References (52)

1. Bitterman K.J., et al. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem. 2002, 277:45099-45107.
2. Bolivar V.J., et al. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice. Brain Res. 2004, 1005:29-35.
3. Bortvedt S.F., et al. Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease. Neurobiol. Dis. 2010, 40:130-134.
4. Butler R., Bates G.P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci. 2006, 7:784-796.
5. Carter R.J., et al. Motor coordination and balance in rodents. Curr. Protoc. Neurosci. 2001, Chapter 8(Unit 8 12).
6. Cha J.H. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000, 23:387-392.
7. Cui L., et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
8. Davies S.W., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
9. Desplats P.A., et al. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J. Neurochem. 2006, 96:743-757.
10. DiFiglia M., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
11. Dillin A., Kelly J.W. Medicine. The yin-yang of sirtuins. Science 2007, 317:461-462.
12. Duyao M., et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet. 1993, 4:387-392.
13. Erb C., Klein J. Enhancement of brain choline levels by nicotinamide: mechanism of action. Neurosci. Lett. 1998, 249:111-114.
14. Ferrante R.J., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 2003, 23:9418-9427.
15. Ghosh S., Feany M.B. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. Hum. Mol. Genet. 2004, 13:2011-2018.
16. Green K.N., et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J. Neurosci. 2008, 28:11500-11510.
17. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 2006, 444:868-874.
18. Handschin C., Spiegelman B.M. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr. Rev. 2006, 27:728-735.
19. Hockly E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 2003, 100:2041-2046.
20. Iannicola C., et al. Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease. J. Neurochem. 2000, 75:830-839.
21. Imai S., et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000, 403:795-800.
22. Jia H., et al. High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease. J. Neurosci. Res. 2008, 86:2083-2090.
23. Knip M., et al. Safety of high-dose nicotinamide: a review. Diabeto 2000, 43:1337-1345.
24. Lagouge M., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
25. Leone T.C., et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 2005, 3:e101.
26. Lin J., et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 2004, 119:121-135.
27. Luthi-Carter R., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 2000, 9:1259-1271.
28. Mangiarini L., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
29. McGill J.K., Beal M.F. PGC-1alpha, a new therapeutic target in Huntington's disease?. Cell 2006, 127:465-468.
30. McLear J.A., et al. Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease. FASEB J. 2008, 22:2003-2011.
31. Nemoto S., et al. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J. Biol. Chem. 2005, 280:16456-16460.
32. Nonomura T., et al. Brain-derived neurotrophic factor regulates energy expenditure through the central nervous system in obese diabetic mice. Int. J. Exp. Diabetes Res. 2001, 2:201-209.
33. Orr A.L., et al. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci. 2008, 28:2783-2792.
34. Pabello N.G., et al. Regional expression of constitutive and inducible transcription factors following transient focal ischemia in the neonatal rat: influence of hypothermia. Brain Res. 2005, 1038:11-21.
35. Pallas M., et al. Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience 2008, 154:1388-1397.
36. Pallos J., et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 2008, 17:3767-3775.
37. Rine J., et al. A suppressor of mating-type locus mutations in Saccharomyces cerevisiae: evidence for and identification of cryptic mating-type loci. Genetics 1979, 93:877-901.
38. Ross C.A., Thompson L.M. Transcription meets metabolism in neurodegeneration. Nat. Med. 2006, 12:1239-1241.
39. Roth S.Y., et al. Histone acetyltransferases. Annu. Rev. Biochem. 2001, 70:81-120.
40. Shao J., Diamond M.I. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet. 2007, 16(Spec No. 2):R115-R123.
41. Snyder-Keller A., et al. Early or late-stage anti-N-terminal huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J. Neuropat. Exp. Neuro. 2010, 69(10):1078-1085.
42. Southwell A.L., et al. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J. Neurosci. 2009, 29:13589-13602.
43. Steffan J.S., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
44. Szapacs M.E., et al. Exploring the relationship between serotonin and brain-derived neurotrophic factor: analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression. J. Neurosci. Methods 2004, 140:81-92.
45. Taylor D.M., et al. Biological and potential therapeutic roles of sirtuin deacetylases. Cell. Mol. Life Sci. 2008, 65:4000-4018.
46. Turmaine M., et al. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 2000, 97:8093-8097.
47. Weiss A., et al. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J. Neurochem. 2008, 104:846-858.
48. Weydt P., et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 2006, 4:349-362.
49. Wolfgang W.J., et al. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc. Natl Acad. Sci. USA 2005, 102:11563-11568.
50. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009, 5:311-322.
51. Zuccato C., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
52. Zuccato C., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 2003, 35:76-83.